Recent Insider Transactions - Climb Bio (NASDAQ: CLYM) - Life Science Report

C4 Therapeutics

Company

Name / Role

Date

Type

Price

# Shares

Value

Balance

NASDAQ CLYM Climb Bio

RA CAPITAL MANAGEMENT, L.P. / director, 10 percent owner:

12/11/2025

Buy

$0.0001

20.44M

$2K

20.44M

NASDAQ CLYM Climb Bio

RA CAPITAL MANAGEMENT, L.P. / director, 10 percent owner:

12/12/2025

Buy

$2.86

101,462

$290K

3.40M

NASDAQ CLYM Climb Bio

RA CAPITAL MANAGEMENT, L.P. / director, 10 percent owner:

12/11/2025

Buy

$2.18

213,099

$465K

3.29M

Research Tools

News & Announcements

Popular Topics

Miscellaneous